We observed a total of eight genes with significant differences in mutation frequencies between CXCR3-high and CXCR3-low patients, which were TP53 (61% vs 37%, p < 0.05), FGFR3 (11% vs 29%, p < 0.05), MDM2 (4% vs 12%, p < 0.05), and FBXW7 (9% vs 1%, p < 0.05) in the ICI cohort; and TP53 (48% vs 36%, p < 0.05), EP300 (17% vs 9%, p < 0.05), FGFR3 (6% vs 21%, p < 0.05), RB1 (17% vs 8%, p < 0.05), KMT2A (14% vs 6%, p < 0.05), and CREBPP (13% vs 6%, p < 0.05) in the TCGA BLCA cohort. This evidence concerns the gene EP300 and bladder transitional cell carcinoma.